Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HX009 |
| Synonyms | |
| Therapy Description |
HX009 is a bispecific antibody that targets both PD-1 (PDCD1) on T lymphocytes and CD47 expressed on tumor cells, potentially leading to activation of macrophages, increased phagocytosis of CD47-positive cancer cells, and activation of effector T cell and cytotoxic T-lymphocyte (CTL) mediated antitumor responses (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HX009 | HX 009|HX-009 | CD47 Antibody 31 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 137 | HX009 is a bispecific antibody that targets both PD-1 (PDCD1) on T lymphocytes and CD47 expressed on tumor cells, potentially leading to activation of macrophages, increased phagocytosis of CD47-positive cancer cells, and activation of effector T cell and cytotoxic T-lymphocyte (CTL) mediated antitumor responses (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|